Self-Injections Global Market Report 2024

The global self-injections market has grown exponentially in recent years. It will grow from $50.72 billion in 2023 to $63.54 billion in 2024 at a compound annual growth rate (CAGR) of 25.3%. The growth in the historical period can be attributed to various factors including the increase in chronic diseases, enhanced patient empowerment, supportive regulations, a preference for home healthcare options, and the focus on cost-effectiveness in healthcare solutions.

The global self-injections market is expected to see exponential growth in the next few years. It will grow to $147.24 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The anticipated growth in the upcoming period can be credited to factors like the impact of the pandemic leading to the growth of remote treatment options, expanding into emerging markets, a shift towards patient-centric healthcare services, advantages in drug delivery systems, and the ongoing trend of personalized medicine. Key trends expected in the forecast period encompass the integration of smart technologies, increased usage of biologics, the development of smaller and wearable medical devices, improved safety features, and a higher adoption rate of autoinjectors.

The self-injections market is expected to witness significant growth due to the increasing number of diabetic patients. Diabetes, a condition characterized by inadequate insulin production by the pancreas, affects a substantial population globally. To manage this condition effectively, diabetic patients often use self-injections to administer insulin and other medications, enabling them to control blood sugar levels independently. The International Diabetes Federation (IDF) reported in 2021 that 567 million adults aged 20 to 79 years are currently living with diabetes, and this number is projected to reach 643 million by 2030 and 783 million by 2045. The rising prevalence of diabetes is a key driver propelling the growth of the self-injections market.

The growth of telehealth and telemedicine is also contributing to the expansion of the self-injections market. Telehealth involves the use of telecommunications technology for providing various healthcare services remotely, while telemedicine specifically focuses on remote clinical consultations and healthcare delivery. These digital health platforms play a crucial role in enabling virtual consultations, allowing healthcare providers to remotely prescribe self-injectable medications. Patients benefit from virtual training sessions, ensuring proper administration of self-injections. Telehealth facilitates real-time monitoring of patient adherence, continuous disease management, and convenient access to telepharmacy services for medication delivery. The adoption of telehealth increased significantly in 2021, with 37.0% of adults in the United States utilizing telemedicine within the preceding 12 months, as reported by the Centers for Disease Control and Prevention (CDC). The convenience and accessibility offered by telehealth contribute substantially to the growth of the self-injections market.

Innovation in insulin injection solutions is a key trend in the self-injections market, with major companies focusing on developing new products to gain a competitive edge. For example, in September 2022, Terumo Corporation, a Japan-based medical device company, launched FineGlide, a sterile pen needle designed for patients requiring regular insulin injections or other self-medication. FineGlide prioritizes patient comfort by featuring a 3-bevel super sharp needle with a high-grade silicone surface, ensuring gentleness during injections. The inclusion of Thin Wall Technology improves flow rate and reduces injection force, enhancing the overall experience for patients and promoting drug compliance. This focus on product innovation demonstrates the commitment of major companies to meet the evolving needs of patients in the self-injections market.

Major players in the self-injections market are focusing on the development of smart injecting devices to gain a competitive advantage. In March 2022, Pfizer Inc., a prominent US-based pharmaceutical company, introduced ENBREL SmartClic in Australia. This innovative self-injecting device is designed for patients undergoing treatment with ENBREL, a tumor necrosis factor (TNF) inhibitor prescribed for conditions like Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and Psoriatic Arthritis (PsA). ENBREL SmartClic features an automated, reusable design with user-friendly elements, including a one-button initiation, a larger grip compared to the Enbrel Auto-Injector, and injection speed control. The device is accompanied by a smartphone app, providing additional features such as reminders, injection history recording, site tracking, and streamlined reports. Patients can access these features on their smartphones and share the information with healthcare professionals, enhancing the overall self-injection experience for those dealing with chronic inflammatory diseases.

In June 2022, Dr. Reddy Labs, an India-based pharmaceutical manufacturer, made a significant acquisition by purchasing an injectable portfolio from Eton Pharma for $50 million. This strategic move by Dr. Reddy's aimed to accelerate and expand the availability of affordable medications for patients. The acquisition included new portfolios such as injections and recipes, allowing Dr. Reddy's to diversify its product offerings and strengthen its position in the pharmaceutical market. Eton Pharma, a US-based pharmaceutical manufacturer, contributed to Dr. Reddy's efforts to broaden its pharmaceutical portfolio, signaling a strategic expansion into injectable medications.

Major companies operating in the self-injections market report are AbbVie Inc., Antares Pharma Inc., Baxter International Inc., Bayer AG, Becton Dickinson and Company, Bristol-Myers Squibb Company, Credence MedSystems Inc., Dali Medical Devices Ltd., Eli Lilly and Company, Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Merck & Co. Inc., Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet Inc., Recipharm AB, Schott AG, Scintilla Pharmaceuticals Inc., SHL Group.Limited, Terumo Corporation, West Pharmaceutical Services Inc., Wilhelm Haselmeier GmbH & Co. KG, Ypsomed Holding AG, APTAR PHARMA INDIA PVT Ltd., Bespak Europe Ltd., Bioject Medical Technologies Inc., Catalent Inc., Crossject SA, Injex Pharma AG, Medeca Pharma AB, Medimop Medical Projects Ltd., Mylan N.V., Nemera Development S.A., Noble Medical Inc.

North America was the largest region in the self injections market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the self-injections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of self-injections encompass devices and formulations. These devices enable patients to self-administer medications that require injection without relying on medical professionals. Self-injection devices are utilized for various routes of administration such as skin, circulatory or musculoskeletal systems, organs, and the central nervous system. Dosage types include single-dose and multi-dose, catering to applications in autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. These devices are distributed through various channels including hospitals, pharmacies, clinics, chemists, and online pharmacies.

This report provides self injections market statistics, including self injections industry global market size, regional shares, competitors with a self injections market share, detailed self injections market segments, market trends and opportunities, and any further data you may need to thrive in the self injections industry. This self injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The self injections market consists of sales of auto-injectors, needle-free injectors, pen injectors and wearable injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.